The burden of disease in seronegative myasthenia gravis: a patient-centered perspective.

ABSTRACT:

Objective

Myasthenia gravis (MG) is an autoimmune disorder primarily caused by autoantibodies against the acetylcholine receptor (AChR). Approximately 15% of MG patients, categorized as seronegative (snMG), lack detectable antibodies. Due to the snMG status, there may be a diagnostic delay. Moreover, there are limited data on treatment response in comparison to AChR-Ab+ patients. This study examines the burden of disease, treatment response, and quality of life of snMG patients in comparison to AChR-ab+ MG patients and healthy controls.

Methods

A questionnaire-based survey was conducted collecting sociodemographic and clinical data including antibody status, therapy, treatment response, and self-rated disease severity along with standardized assessments such as MG-ADL (activ

SUBMITTER: Lehnerer S 

PROVIDER: S-EPMC12011775 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature